This invention relates to devices for providing support for biological tissue, for example to repair spinal compression fractures, and methods of using the same.
Vertebroplasty is an image-guided, minimally invasive, nonsurgical therapy used to strengthen a broken vertebra that has been weakened by disease, such as osteoporosis or cancer. Vertebroplasty is often used to treat compression fractures, such as those caused by osteoporosis, cancer, or stress.
Vertebroplasty is often performed on patients too elderly or frail to tolerate open spinal surgery, or with bones too weak for surgical spinal repair. Patients with vertebral damage due to a malignant tumor may sometimes benefit from vertebroplasty. The procedure can also be used in younger patients whose osteoporosis is caused by long-term steroid treatment or a metabolic-disorder.
Vertebroplasty can increase the patient's functional abilities, allow a return to the previous level of activity, and prevent further vertebral collapse. Vertebroplasty attempts to also alleviate the pain caused by a compression fracture.
Vertebroplasty is often accomplished by injecting an orthopedic cement mixture through a needle into the fractured bone. The cement mixture can leak from the bone, potentially entering a dangerous location such as the spinal canal. The cement mixture, which is naturally viscous, is difficult to inject through small diameter needles, and thus many practitioners choose to “thin out” the cement mixture to improve cement injection, which ultimately exacerbates the leakage problems. The flow of the cement liquid also naturally follows the path of least resistance once it enters the bone—naturally along the cracks formed during the compression fracture. This further exacerbates the leakage.
The mixture also fills or substantially fills the cavity of the compression fracture and is limited to certain chemical composition, thereby limiting the amount of otherwise beneficial compounds that can be added to the fracture zone to improve healing. Further, a balloon must first be inserted in the compression fracture and the vertebra must be expanded before the cement is injected into the newly formed space.
A vertebroplasty device and method that eliminates or reduces the risks and complexity of the existing art is desired. A vertebroplasty device and method that is, not based on injecting a liquid directly into the compression fracture zone is desired.
An expandable support device for performing completely implantable spinal repair is disclosed. The device may include a near end portion and a far end portion with a number of backbone struts extending therebetween. The near and far end portions may be closed or have passage openings. In one variation of the invention the end portions can be non-expandable and can cause the implant to form a tapered profile when expanded. Adjacent backbone struts in the implant can be connected by a number of deformable-support struts. The adjacent backbone struts can be affixed together or integral (e.g., when laser cut from a tube or other extrusion type piece).
The structure of the implant device can permit expansion a number of directions. Variations of the implant can assume different cross-sectional shapes, where such shapes include a square, rectangular, triangular, or any such type of polygon where the sides are defined by the adjacent backbone struts and associated connecting support struts. Furthermore, the shapes may also be rounded, tapered, rectangular (e.g., where the aspect ratio may not be 1 to 1.)
An expandable support device for placement within or between spinal vertebral bodies is disclosed. The device can have a radially non-expandable near end portion, a radially non-expandable far end portion and a longitudinal axis extending therebetween. The device can have backbone struts parallel to the longitudinal axis. The backbone struts can each have a near end integral with the near end portion and a far end integral with the far end portion. The device can have deformable support struts located between each adjacent backbone strut. The support struts can have a support strut width perpendicular to the longitudinal axis. The support struts can have a support strut thickness parallel to the longitudinal axis. The support strut width can be greater than the support strut thickness. Each support strut can be deformable such that, upon longitudinal expansion of the expandable support device from a radially expanded configuration, the adjacent backbone struts approach each other while the support struts deform. One or more of the support struts can have a bend when the device is in a radially contracted configuration. The bend can define an edge having a surface that is coincidental with the outer surface of the expandable support device. When the device is in a radially contracted configuration a first length of the backbone struts can be the same shape as the first length of the backbone struts when the device is in a radially expanded configuration. When the device is in a radially expanded configuration, the device can have a lumen along the longitudinal axis. The lumen can be at least partially filled with a filler. An outer cross section of the device perpendicular to the longitudinal axis when the device is in a radially expanded configuration can be quadrilateral. Lengths of at least two backbone struts can be parallel with each other when the device is in a radially expanded configuration.
An expandable support device for placement within or between spinal vertebral bodies is disclosed. The device can have a radially non-expandable near end portion, a radially non-expandable far end portion and a longitudinal axis extending therebetween. The device can have backbone struts parallel to the longitudinal axis. The backbone struts can each have a near end integral with the near end portion and a far end integral with the far end portion. The device can have deformable support struts located between each adjacent backbone strut. Each support strut can be deformable such that, upon longitudinal expansion of the expandable support device from a radially expanded configuration, the adjacent backbone struts approach each other while the support struts deform. When the device is in a radially expanded configuration, the device can have a lumen along the longitudinal axis. The lumen can be at least partially filled with a filler. An outer cross section of the device perpendicular to the longitudinal axis when the device is in a radially expanded configuration can be quadrilateral. At least one support strut can have a bend when the device is in a radially contracted configuration. The bend can defines an edge having a surface that is coincidental with the outer surface of the expandable support device.
An expandable support device for placement within or between spinal vertebral bodies is disclosed. The device can have a radially non-expandable near end portion, a radially non-expandable far end portion and a longitudinal axis extending therebetween. The device can have backbone struts parallel to the longitudinal axis. The backbone struts can each have a near end integral with the near end portion and a far end integral with the far end portion. The device can have deformable support struts located between each adjacent backbone strut. At least a first support strut and a second support strut located between an adjacent pair of backbone struts can be flat when the device is in a radially expanded configuration. Each support strut can be deformable such that, upon longitudinal expansion of the expandable support device from a radially expanded configuration, the adjacent backbone struts approach each other while the support struts deform. When the device is in a radially contracted configuration a first length of the backbone struts can be the same shape as the first length of the backbone struts when the device is in a radially expanded configuration. When the device is in a radially expandable configuration, the device can have a lumen along the longitudinal axis. The lumen can be at least partially filled with a filler. An outer cross section of the device perpendicular to the longitudinal axis when the device is in a radially expanded configuration can be quadrilateral. At least one support strut can have a bend when the device is in a radially contracted configuration. The bend can define an edge having a surface that is coincidental with the outer surface of the expandable support device. A flat plane can be defined by the outer surfaces of the support struts between a first backbone strut and a second backbone strut adjacent to the first backbone strut.
A method for repairing a damaged section of a spine is also disclosed. The method can include expanding an expandable support device in a treatment site such as a damaged section of bone (e.g., vertebra) or soft tissue (e.g., vertebral disc). The expandable support device can be loaded on a balloon during the expanding. The expansion of the device may be accomplished as described herein. For example, the expansion may include can include inflation of a balloon-type expansion device. Inflating the balloon can include inflating the balloon equal to or greater than about 5,000 kPa of internal pressure, or equal to or greater than about 10,000 kPa of internal pressure.
Expandable support devices for orthopedic applications, deployment tools and methods for using that same that can be deployed in a minimally invasive procedure are disclosed. For example, the expandable support devices can be deployed through 0.25 in. to 0.5 in. incisions. The expandable support devices can be, for example, metal and/or polymer self-assembling, self-forming structures. Imaging modalities can be used to maneuver the expandable support device inside the patient.
Further, expandable support devices, deployment tools and methods are disclosed for removing, resizing, and repositioning the expandable support devices are disclosed.
The expandable support devices 2 can be used to provide structural reinforcement from inside one or more bones, as a replacement for one or more bones, or between bones. The expandable support devices can be used for a variety of orthopedic locations, such as in the vertebral column, for example, to treat compression fractures. Examples of expandable support devices and methods for use of expandable support devices, as well as devices for deploying the expandable support devices include those disclosed in the following applications which are all incorporated herein in their entireties: PCT Application Nos. US2005/034115, filed 21 Sep. 2005; US2005/034742, filed 26 Sep. 2005; US2005/034728, filed 26 Sep. 2005; US2005/037126, filed 12 Oct. 2005; U.S. Provisional Application Nos. 60/675,543, filed 27 Apr. 2005; 60/723,309, filed 4 Oct. 2005; 60/675,512, filed 27 Apr. 2005; 60/699,577, filed 14 Jul. 2005; 60/699,576, filed 14 Jul. 2005; and 60/752,183 filed 19 Dec. 2005.
The expandable support device 2 can have a plurality of backbone struts 12. The backbone struts 12 can connect a near end portion 13 and a far end portion 14. The backbone struts 12 can each have a near end and a far end affixed to the respective end portions 13 and 14. The expandable support device 2 can be constructed of separate structures that are fixed, integrated or otherwise joined together. The expandable support device 2 can be fabricated from a uniform stock of material (e.g., via laser cutting, or electrical discharge machining (EDM)). Adjacent backbone struts can be joined by a number of deformable support struts 10. The support struts 10 can have, a thinner cross sectional thickness than most of the remainder of the stent. This feature allows for pre-determined deformation of the stent 2 to take place.
The support struts 10 may also serve to distribute load across the backbone strut. In such cases, the number of support struts will determine the degree to which the backbone struts are supported.
The expansion ratio of the expandable support device 2 can be, for example, about 3 or about 4 times the initial diameter of the expandable support device 2. The expansion ratio can be selected as required for the particular procedure. For example, in the pre-expanded configuration the expandable support device 2 can have an initial diameter of about 6.3 mm (0.25 in.), while in the expanded configuration, the diameter can be about 9.5 mm, (0.37 in.). In a further example, the expandable support device 2 can have an initial diameter of about, 5 mm (0.2 in.), while in the expanded configuration, the diameter can be about 20 mm (0.8 in.).
In the pre-expanded configuration, the cross-sectional shape of the expandable support device 2 can be circular, triangular, oval, rectangular, square, or any type of polygon and/or rounded, and/or tapered shape. Upon expansion, the expandable support device 2 can form a polygon-type shape, or other shape as discussed herein.
The adjacent backbone struts 12 and accompanying support struts 10 can form a side of the implant. Although the variation illustrated in
Any portion of the expandable support device 2 can have one or more ingrowth ports (not shown). The ingrowth ports can be configured to encourage biological tissue ingrowth therethrough during use. The ingrowth ports can be configured to releasably and/or fixedly attach to a deployment tool or other tool. The ingrowth ports can be configured to increase, and/or decrease, and/or focus pressure against the surrounding biological tissue during use. The ingrowth ports can be configured to increase and/or decrease the stiffness of either the backbone or support struts.
The expandable support device 2 can have any number of support struts 10. The support struts 10 can have a substantially “V”-like shape that deforms or expands as the implant expands, such as shown in
The expandable support device 2 can have a wall thickness from about 0.25 mm (0.098 in.) to about 5 mm (0.2 in.), for example about 1 mm (0.04 in.). The expandable support device 2 can have an inner diameter (e.g., between farthest opposing backbone structures). The inner diameter can be from about 0.1 mm (0.04 in.) to about 30 mm (1.2 in.), for example about 6 mm (0.2 in.). The wall thickness and/or the inner diameter can vary with respect to the length along the longitudinal axis 4. The wall thickness and/or the inner diameter can vary with respect to the angle formed with a plane parallel to the longitudinal axis 4. The wall thickness can be reduced at points where deformation is desired. For example, the wall thickness of the support struts 10 can be reduced where the backbone structure meets the end portions.
The expandable support device 2 can have one or more protrusions on the surface of the expandable support device 2. The protrusions can have features such as tissue hooks, and/or barbs, and/or cleats. The protrusions can be integral with and/or fixedly or removably attached to the expandable support device 2. The expandable support device 2 can be configured (e.g., on the support struts 10 or other parts of the implant) to burrow into soft bone (e.g., cancellous or diseased), for example, until the device fully expands, or until the device hits the harder vertebral endplates.
Any or all elements of the expandable support device 2 and/or other devices or apparatuses described herein (e.g., including all deployment tools and their elements described below) can be made from, for example, a single or multiple stainless steel alloys, nickel titanium alloys (e.g., Nitinol), cobalt-chrome alloys (e.g., ELGILOY® from Elgin Specialty Metals, Elgin, Ill.; CONICHROME® from Carpenter Metals Corp., Wyomissing, Pa.), nickel-cobalt alloys (e.g., MP35N® from Magellan Industrial Trading Company, Inc., Westport, Conn.), molybdenum alloys (e.g., molybdenum TZM alloy, for example as disclosed in International Pub. No. WO 03/082363 A2, published 9 Oct. 2003, which is herein incorporated by reference in its entirety), tungsten-rhenium alloys, for example, as disclosed in International Pub. No. WO 03/082363, polymers such as polyethylene teraphthalate (PET), polyester (e.g., DACRON® from E. I. Du Pont de Nemours and Company, Wilmington, Del.), polypropylene, aromatic polyesters, such as liquid crystal polymers (e.g., Vectran, from Kuraray Co., Ltd., Tokyo, Japan), ultra high molecular weight polyethylene (i.e., extended chain, high-modulus or high-performance polyethylene) fiber and/or yarn (e.g., SPECTRA® Fiber and SPECTRA® Guard, from Honeywell International, Inc., Morris Township, N.J., or DYNEEMA® from Royal DSM N.V., Heerlen, the Netherlands), polytetrafluoroethylene (PTFE), expanded PTFE (ePTFE), polyether ketone (PEK), polyether ether ketone (PEEK), poly ether ketone ketone (PEKK) (also poly aryl ether ketone ketone), nylon, polyether-block co-polyamide polymers (e.g., PEBAX® from ATOFINA, Paris, France), aliphatic polyether polyurethanes (e.g., TECOFLEX® from Thermedics Polymer Products, Wilmington, Mass.), polyvinyl chloride (PVC), polyurethane, thermoplastic, fluorinated ethylene propylene (FEP), absorbable or resorbable polymers such as polyglycolic acid (PGA), poly-L-glycolic acid (PLGA), polylactic acid (PLA), poly-L-lactic acid (PLLA), polycaprolactone (PCL), polyethyl acrylate (PEA), polydioxanone (PDS), and pseudo-polyamino tyrosine-based acids, extruded collagen, silicone, zinc, echogenic, radioactive, radiopaque materials, a biomaterial (e.g., cadaver tissue, collagen, allograft, autograft, xenograft, bone cement, morselized bone, osteogenic powder, beads of bone) any of the other materials listed herein or combinations thereof. Examples of radiopaque materials are barium sulfate, zinc oxide, titanium, stainless steel, nickel-titanium alloys, tantalum and gold.
Any or all elements of the expandable support device 2 and/or other devices or apparatuses described herein (e.g., including all deployment tools and their elements described below), can be, have, and/or be completely or partially coated with agents and/or a matrix a matrix for cell ingrowth or used with a fabric, for example a covering (not shown) that acts as a matrix for cell ingrowth. The matrix and/or fabric can be, for example, polyester (e.g., DACRON® from E. I. Du Pont de Nemours and Company, Wilmington, Del.), polypropylene, PTFE, ePTFE, nylon, extruded collagen, silicone or combinations thereof.
The expandable support device 2 and/or elements of the expandable support device 2 and/or other devices or apparatuses described herein (e.g., including all deployment tools and their elements described below) and/or the fabric can be filled, coated, layered and/or otherwise made with and/or from cements, fillers, glues, and/or an agent delivery matrix known to one having ordinary skill in the art and/or a therapeutic and/or diagnostic agent. Any of these cements and/or fillers and/or glues can be osteogenic and osteoinductive growth factors.
Examples of such cements and/or fillers includes bone chips, demineralized bone matrix (DBM), calcium sulfate, coralline hydroxyapatite, biocoral, tricalcium phosphate, calcium phosphate, polymethyl methacrylate (PMMA), biodegradable ceramics, bioactive glasses, hyaluronic acid, lactoferrin, bone morphogenic proteins (BMPs) such as recombinant human bone morphogenetic proteins (rhBMPs), other materials described herein, or combinations thereof.
The agents within these matrices can include any agent disclosed herein or combinations thereof, including radioactive materials; radiopaque materials; cytogenic agents; cytotoxic agents; cytostatic agents; thrombogenic agents, for example polyurethane, cellulose acetate polymer mixed with bismuth trioxide, and ethylene vinyl alcohol; lubricious, hydrophilic materials; phosphor cholene; anti-inflammatory agents, for example non-steroidal anti-inflammatories (NSAIDs) such as cyclooxygenase-1 (COX-1) inhibitors (e.g., acetylsalicylic acid, for example ASPIRIN® from Bayer AG, Leverkusen, Germany; ibuprofen, for example ADVIL® from Wyeth, Collegeville, Pa.; indomethacin; mefenamic acid), COX-2 inhibitors (e.g., VIOXX® from Merck & Co. Inc. Whitehouse Station, N.J.; CELEBREX® from Pharmacia Corp., Peapack, N.J.; COX-1 inhibitors); immunosuppressive agents, for example Sirolimus (RAPAMUNE®, from Wyeth, Collegeville, Pa.), or matrix metalloproteinase (MMP) inhibitors (e.g., tetracycline and tetracycline derivatives) that act early within the pathways of an inflammatory response. Examples of other agents are provided in Walton et al, Inhibition of Prostoglandin E2 Synthesis in Abdominal Aortic Aneurysms, Circulation, Jul. 6, 1999, 48-54; Tambiah et al, Provocation of Experimental Aortic Inflammation Mediators and Chlamydia Pneumoniae, Brit. J. Surgery 88 (7), 935-940; Franklin et al, Uptake of Tetracycline by Aortic Aneurysm Wall and Its Effect on Inflammation and Proteolysis, Brit. J Surgery 86 (6), 771-775; Xu et al, Sp1 Increases Expression of Cyclooxygenase-2 in Hypoxic Vascular Endothelium, J. Biological Chemistry 275 (32) 24583-24589; and Pyo et al, Targeted Gene Disruption of Matrix Metalloproteinase-9 (Gelatinase B) Suppresses Development of Experimental Abdominal Aortic Aneurysms, J. Clinical Investigation 105 (11), 1641-1649 which are all incorporated by reference in their entireties.
Method of Use
The expandable support device 2 can be deployed and/or expanded with a force from a mechanical actuation device (e.g., as opposed to the balloon expansion). For example, the ends of the expandable support device 2 can move, or be moved, together to expand the backbone struts outward. The expandable support device 2 can be configured to be self-expand upon the removal of a restraint (e.g., when the expandable support device 2 is constructed from a resilient or super-elastic material). The expandable support device 2 can be made from a shape memory alloy that can have a pre-determined transition temperature such that expansion takes place due to temperature changes passively (e.g., from the patient's body heat) or actively (e.g., from thermal and/or electrical energy delivered to the expandable support device 2 from outside the patient) created during or after implantation.
The expandable support device 2 can be locked into the expanded configured with a locking structure (e.g., a center strut, ratchet type mechanism, screw, locking arm, combinations thereof that can be integral with or separate from the remainder of the expandable support device 2. The expandable-support device 2 can be “locked” into the expanded position by filing the expandable support device 2 with cement, filler (bone chips, calcium sulfate, coralline hydroxyapatite, Biocoral tricalcium phosphate, calcium phosphate, PMMA, bone morphogenic proteins, other materials described herein, or combinations thereof.
The deployment tool 38 can be a pair of wedges, an expandable jack, other expansion tools, or combinations thereof.
An access tool 54 can be used to gain access to the damage site 52 and or increase the size of the damage site 52 to allow deployment of the expandable support device 2. The access tool 54 can be a rotating or vibrating drill 56 that can have a handle 58. The drill 56 can be operating, as shown by arrows 60. The drill 56 can then be translated, as shown by arrow 62, toward and into the vertebra 48 so as to pass into the damage site 52.
A second deployment tool 38b can enter through a second incision 66b (as shown) in the skin 68 on the posterior or the first incision 66a. The second deployment tool 38b can be translated through muscle (not shown), around nerves 72, and anterior of the vertebral column 46. The second deployment tool 38b can be steerable. The second deployment tool 38b can be steered, as shown by arrow 74, to align the distal tip of the second expandable support device 2b with a second access port 64b on a second damage site 52b. The second access port 64b can face anteriorly. The second deployment tool 38b can translate, as shown by arrow 76, to position the second expandable support device 2 in the second damage site 52b.
The vertebra 48 can have multiple damage sites 52 and expandable support devices 2 deployed therein. The expandable support devices 2 can be deployed from the anterior, posterior, either or both lateral, superior, inferior, any angle, or combinations of the directions thereof.
The first access port 64a can be substantially centered with respect to the first damage site 52a. The first expandable support device (not shown) can expand, as shown by arrows 78, substantially equidirectionally, aligned with the center of the first access port 64a. The second access port 64b can be substantially not centered with respect to the second damage site 52b. The second expandable support device (not shown) can substantially anchor to a side of the damage site 52 and/or the surface of the disc 50, and then expand, as shown by arrows 80, substantially directionally away from the disc 50.
The access port 64 can have an access port diameter 82. The access port diameter 82 can be from about 1.5 mm (0.060 in.) to about 40 mm (2 in.), for example about 8 mm (0.3 in.). The access port diameter 82 can be a result of the size of the access tool 54. After the expandable support device 2 is deployed, the damage site 52 can have a deployed diameter 84. The deployed diameter 84 can be from about 1.5 mm (0.060 in.) to about 120 mm (4.7 in.), for example about 20 mm (0.8 in.). The deployed diameter 84 can be greater than, equal to, or less than the access port diameter 82.
The expandable support device 2 can be configured to create a cavity or otherwise displaces bone and/or tissue to form a space within the target sites during deployment (e.g., (luring radial expansion). For example, the struts of the expandable support device 2 can be configured so the radial expansion of the expandable support device 2 can move and/or compact bone/tissue. The struts can be configured to be narrow such that, on expansion, the struts move a relatively smaller amount of bone and/or tissue such that the struts do not compact the tissue.
After the expandable support device 2 has been initially deployed (i.e., inserted, and/or radially expanded) into the treatment site, the expandable support device 2 can be retracted, removed, resized, repositioned, and combinations thereof. The expandable support device 2 can be retracted and/or removed, and/or resized, and/or repositioned, for example, about 0 to about 2 months after initial deployment and/or the latest removal, and/or resizing, and/or repositioning.
The first engagement element 100a can attach to the proximal end of the expandable support device 2. The first engagement element 100a can be an abutment. The second engagement element 100b can attach to the distal end of the expandable support device 2. The second engagement element 100b can be a threaded outer surface. The expandable support device 2 can have a threaded inner radius, for example, that can be configured to engage the threaded outer surface of the second engagement element 100b.
The expandable support device 2 can be withdrawn from the target site, and/or retracted into the engagement device 38.
The deployment tool 38 can be rotatably attached to and detached from the expandable support device 2. The outer handle 104 can contact the expandable support device 2 by completely encircling the first engagement element 100a, and/or by discretely contacting the first engagement element 100a, for example with a set of individual radially translatable arms that can be detached from the first engagement element 100a by translating the arms radially outward (or inward if necessary) from the first engagement element 100a.
The outer handle 104 and inner rod 102 can be detached and/or reattached in any combination to the expandable support device 2. For example, the expandable support device 2 can be positioned in the target site. The expandable support device 2 can then be radially expanded (e.g., by applying a longitudinally compressive force). The inner rod 102 can then be detached from the expandable support device 2. The expandable support device 2 can be repositioned by manipulating the expandable support device 2 with the outer handle 104. The outer handle 104 can then be detached from the expandable support device 2 and the deployment tool can be withdrawn from the target site and/or the inner rod 102 can be reattached to the expandable support device 2 and the expandable support device can be radially expanded, and/or radially contracted, and/or repositioned within the target site, and/or removed from the target site.
The expandable support device 2 can, be configured to radially contract when a rotational (e.g., twisting) force is applied to the expandable support device 2. The expandable support device 2 can have a completely or partially coiled or otherwise spiral configuration. The expandable support device 2 can have a radius or height reduction based on a twisting effect.
The expandable support device 2 can be configured to be overdeployable. When the expandable support device 2 is overdeployed, the expandable support device 2 can return to a substantially pre-deployment configuration (e.g., having a pre-deployment radius, but in a different configuration otherwise).
The internal control shaft 132 can have the first and second engagement elements 100a and 100b. The expandable support element 2 can have discrete first and second receivers 136a and 136b configured to removably attach to the first and second engagement elements 100a and 100b, respectively. For example, the first and second receivers 136a and 136b can be threaded.
The first engagement element 100a can have a stop or brake thread 140, for example configured to interference fit the first receiver 136a.
In an undeployed or pre-deployed (e.g., radially contracted) configuration, the second engagement element 100b can be attached to the second receiver 136b. The first engagement element 100a can be unattached to the first receiver 136a.
The deployment tool 38 can be removed from the target site. The expandable support device 2 can remain in the target site, for example, fixed in the deployed configuration (e.g., unable to substantially radially or longitudinally expand or contract) and/or bolstered by the inner control shaft 132. The deployment tool 38 can re-engage the expandable support device 2 and the above steps can be reversed to radially contract and retract, reposition, and/or remove the expandable support device 2 in or from the target site.
The expandable support device 2 can have a mechanical key or locking bar that can fix the expandable support device 2 in an expanded or otherwise deployed configuration. When the key or locking bar is removed from the expandable support device 2, the expandable support device 2 can be repositioned, and/or removed and/or resized (e.g., deconstructed), for example, automatically, resiliently radially compressed.
The expandable support device can be subject to fatigue, for example, to increase material brittleness resulting in fracture. The fractured pieces of the expandable support device can be removed, for example, by suction and irrigation. The engagement element can be a small grabber or gripper. The engagement element can induce oscillating motion in the struts. The oscillating motion can cause strut fatigue and failure, for example in the struts and/or in the joints. The oscillating motion can be ultrasonic, mechanical, hydraulic, pneumatic, or combinations thereof.
The expandable support device 2 can have receiving elements to engage the engagement elements. For example, the receiving elements can be hooks, barbs, threads, flanges, wedge shaped slots, dovetails, hinges, key holes, or combinations thereof.
The expandable support device 2 can have a leader. The leader can be a heavy wire. The leader can guide the engagement device into and/or over the implant. The engagement device 38 can radially contract the implant, for example, using a method described herein. The engagement device 38 and/or another tool can drill or otherwise destroy bone and/or other tissue to access the expandable support device 2.
The tissue surrounding the expandable support device 2 can be destroyed (e.g., chemically and/or electrically and/or thermally, such as by cauterization or electro-cauterization). The expandable support device 2 can be removed and/or repositioned and/or resized once the surrounding tissue is completely or substantially destroyed.
The expandable support device 2 can be mechanically destroyed. For example, the expandable support device can be mechanically compressed, for example by applying external radially and/or axially (i.e., longitudinally) contracting jaws. A snipper and/or microgrinder and/or saw can mechanical destroy the expandable support device.
The expandable support device 2 can be chemically destroyed using RF energy. For example UV energy can be delivered to dissolve a plastic expandable support device.
The expandable support device 2 can be biodegradable. The expandable support device 2 can be made from biodegradable materials known to those having ordinary skill in the art. The expandable support device 2 can be made from a magnesium based alloy that can degrade or a biodegrading polymer for example, PGA, PLA, PLLA, PCL.
The expandable support device 2 can be configured to device designed to dissolve when exposed to selected materials (e.g., in solution). For example, acetone can be applied to the expandable support device (e.g., made from PMMA). The surrounding tissues can be protected and/or the expandable support device can be fluidly contained before the dissolving solution is applied.
The expandable support device 2 can be dissolved, for example, by exposing the expandable support device to an electrolyte and electricity.
Imaging methods can be used in combination with the methods for deploying the expandable support device described herein. For example, imaging methods can be used to guide the expandable support device during deployment. The expandable support device 2 can have imaging markers (e.g., echogenic, radiopaque), for example to signal the three-dimensional orientation and location of the expandable support device during use of an imaging modality. Imaging modalities include ultrasound, magnetic resonance imaging (MRI, fMRI), computer tomography (CT scans) and computed axial tomography (CAT scans), radiographs (x-rays), fluoroscopy, diffuse optical tomography, elastography, electrical impedance tomography, optoacoustic imaging, positron emission tomography, and combinations thereof.
It is apparent to one skilled in the art that various changes and modifications can be made to this disclosure, and equivalents employed, without departing from the spirit and scope of the invention. Elements expressed herein as singular or plural can be used in the alternative (i.e., singular as plural and plural as singular). Elements shown with any embodiment are exemplary for the specific embodiment and can be used in combination on or with other embodiments within this disclosure.
This application is a continuation of PCT Application No. PCT/US2006/027601, filed 14 Jul. 2006, which claims the benefit to U.S. Provisional Application Nos. 60/699,576 filed 14 Jul. 2005, and 60/752,183 filed 19 Dec. 2005, which are all herein incorporated by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
646119 | Clamer et al. | Mar 1900 | A |
4204531 | Aginsky | May 1980 | A |
4541423 | Barber | Sep 1985 | A |
4569338 | Edwards | Feb 1986 | A |
4636217 | Ogilvie et al. | Jan 1987 | A |
4653489 | Tronzo | Mar 1987 | A |
4716839 | Catena | Jan 1988 | A |
4716893 | Fischer et al. | Jan 1988 | A |
4725264 | Glassman | Feb 1988 | A |
4733665 | Palmaz | Mar 1988 | A |
4759769 | Hedman et al. | Jul 1988 | A |
4763644 | Webb | Aug 1988 | A |
4863476 | Shepperd | Sep 1989 | A |
4886062 | Wiktor | Dec 1989 | A |
4911718 | Lee et al. | Mar 1990 | A |
4932975 | Main et al. | Jun 1990 | A |
4941466 | Romano | Jul 1990 | A |
4969888 | Scholten et al. | Nov 1990 | A |
5007909 | Rogozinski | Apr 1991 | A |
5015247 | Michelson | May 1991 | A |
5026373 | Ray et al. | Jun 1991 | A |
5059193 | Kuslich | Oct 1991 | A |
5108404 | Scholten et al. | Apr 1992 | A |
5123926 | Pisharodi | Jun 1992 | A |
5139480 | Hickle et al. | Aug 1992 | A |
5171278 | Pisharodi | Dec 1992 | A |
5217483 | Tower | Jun 1993 | A |
5258031 | Salib et al. | Nov 1993 | A |
5273533 | Bonaldo | Dec 1993 | A |
5306278 | Dahl et al. | Apr 1994 | A |
5324295 | Shapiro, III | Jun 1994 | A |
5342348 | Kaplan | Aug 1994 | A |
5345927 | Bonutti | Sep 1994 | A |
5390683 | Pisharodi | Feb 1995 | A |
5390898 | Smedley et al. | Feb 1995 | A |
5397364 | Kozak et al. | Mar 1995 | A |
5425773 | Boyd et al. | Jun 1995 | A |
5454365 | Bonutti | Oct 1995 | A |
5458643 | Oka et al. | Oct 1995 | A |
5480442 | Bertagnoli | Jan 1996 | A |
5484384 | Fearnot | Jan 1996 | A |
5496365 | Sgro | Mar 1996 | A |
5522899 | Michelson | Jun 1996 | A |
5534002 | Brumfield et al. | Jul 1996 | A |
5540690 | Miller et al. | Jul 1996 | A |
5549679 | Kuslich | Aug 1996 | A |
5554191 | Lahille et al. | Sep 1996 | A |
5556413 | Lam | Sep 1996 | A |
5562736 | Ray et al. | Oct 1996 | A |
5562738 | Boyd et al. | Oct 1996 | A |
5571189 | Kuslich | Nov 1996 | A |
5571192 | Schonhoffer | Nov 1996 | A |
5584831 | McKay | Dec 1996 | A |
5591197 | Orth et al. | Jan 1997 | A |
5593409 | Michelson | Jan 1997 | A |
5609356 | Mossi | Mar 1997 | A |
5609635 | Michelson | Mar 1997 | A |
5643264 | Sherman et al. | Jul 1997 | A |
5643312 | Fischell et al. | Jul 1997 | A |
5645560 | Crocker et al. | Jul 1997 | A |
5653763 | Errico et al. | Aug 1997 | A |
5658335 | Allen | Aug 1997 | A |
5665122 | Kambin | Sep 1997 | A |
5669909 | Zdeblick et al. | Sep 1997 | A |
5674295 | Ray et al. | Oct 1997 | A |
5683394 | Rinner | Nov 1997 | A |
5693100 | Pisharodi | Dec 1997 | A |
5702449 | McKay | Dec 1997 | A |
5702453 | Rabbe et al. | Dec 1997 | A |
5741253 | Michelson | Apr 1998 | A |
5749916 | Richelsoph | May 1998 | A |
5772661 | Michelson | Jun 1998 | A |
5776181 | Lee et al. | Jul 1998 | A |
5776197 | Rabbe et al. | Jul 1998 | A |
5776198 | Rabbe et al. | Jul 1998 | A |
5776199 | Michelson | Jul 1998 | A |
5782832 | Larsen et al. | Jul 1998 | A |
5782903 | Wiktor | Jul 1998 | A |
5785710 | Michelson | Jul 1998 | A |
5800520 | Fogarty et al. | Sep 1998 | A |
5824054 | Khosravi et al. | Oct 1998 | A |
5824093 | Ray et al. | Oct 1998 | A |
5827289 | Reiley et al. | Oct 1998 | A |
5827321 | Roubin et al. | Oct 1998 | A |
5853419 | Imran | Dec 1998 | A |
5861025 | Boudghene et al. | Jan 1999 | A |
5863284 | Klein | Jan 1999 | A |
5865848 | Baker | Feb 1999 | A |
5895387 | Guerrero et al. | Apr 1999 | A |
5902475 | Trozera et al. | May 1999 | A |
5916198 | Dillow | Jun 1999 | A |
5972015 | Scribner et al. | Oct 1999 | A |
5980522 | Koros et al. | Nov 1999 | A |
5980550 | Eder et al. | Nov 1999 | A |
5984957 | Laptewicz et al. | Nov 1999 | A |
5993483 | Gianotti | Nov 1999 | A |
6001130 | Bryan et al. | Dec 1999 | A |
6019792 | Cauthen | Feb 2000 | A |
6022376 | Assell et al. | Feb 2000 | A |
6025104 | Fuller et al. | Feb 2000 | A |
6027527 | Asano et al. | Feb 2000 | A |
6036719 | Meilus | Mar 2000 | A |
6039761 | Li et al. | Mar 2000 | A |
6045579 | Hochshuler et al. | Apr 2000 | A |
6053916 | Moore | Apr 2000 | A |
6066154 | Reiley et al. | May 2000 | A |
6077246 | Kullas et al. | Jun 2000 | A |
6080158 | Lin | Jun 2000 | A |
6080193 | Hochshuler et al. | Jun 2000 | A |
6083522 | Chu et al. | Jul 2000 | A |
6086610 | Duerig et al. | Jul 2000 | A |
6090143 | Meriwether et al. | Jul 2000 | A |
6102950 | Vaccaro | Aug 2000 | A |
6113639 | Ray et al. | Sep 2000 | A |
6126689 | Brett | Oct 2000 | A |
6127597 | Beyar et al. | Oct 2000 | A |
6129763 | Chauvin et al. | Oct 2000 | A |
6132465 | Ray et al. | Oct 2000 | A |
6140452 | Felt et al. | Oct 2000 | A |
6146417 | Ischinger | Nov 2000 | A |
6159244 | Suddaby | Dec 2000 | A |
6159245 | Meriwether et al. | Dec 2000 | A |
6168616 | Brown, III | Jan 2001 | B1 |
6171312 | Beaty | Jan 2001 | B1 |
6176882 | Biedermann et al. | Jan 2001 | B1 |
6179874 | Cauthen | Jan 2001 | B1 |
6183506 | Penn et al. | Feb 2001 | B1 |
6183517 | Suddaby | Feb 2001 | B1 |
6193757 | Foley et al. | Feb 2001 | B1 |
6206910 | Berry et al. | Mar 2001 | B1 |
6206924 | Timm | Mar 2001 | B1 |
6224595 | Michelson | May 2001 | B1 |
6224603 | Marino | May 2001 | B1 |
6224604 | Suddaby | May 2001 | B1 |
6224607 | Michelson | May 2001 | B1 |
6235043 | Reiley et al. | May 2001 | B1 |
6241734 | Scribner et al. | Jun 2001 | B1 |
6245101 | Drasler et al. | Jun 2001 | B1 |
6245107 | Ferree | Jun 2001 | B1 |
6248110 | Reiley et al. | Jun 2001 | B1 |
6280456 | Scribner et al. | Aug 2001 | B1 |
6287332 | Bolz et al. | Sep 2001 | B1 |
6293967 | Shanley | Sep 2001 | B1 |
6302914 | Michelson | Oct 2001 | B1 |
6332895 | Suddaby | Dec 2001 | B1 |
6371989 | Chauvin et al. | Apr 2002 | B1 |
6387130 | Stone et al. | May 2002 | B1 |
6395031 | Foley et al. | May 2002 | B1 |
6402750 | Atkinson et al. | Jun 2002 | B1 |
6402785 | Zdeblick et al. | Jun 2002 | B1 |
6409765 | Bianchi et al. | Jun 2002 | B1 |
6419704 | Ferree | Jul 2002 | B1 |
6419705 | Erickson | Jul 2002 | B1 |
6423083 | Reiley et al. | Jul 2002 | B2 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6425919 | Lambrecht | Jul 2002 | B1 |
6428569 | Brown | Aug 2002 | B1 |
6432107 | Ferree | Aug 2002 | B1 |
6436098 | Michelson | Aug 2002 | B1 |
6436140 | Liu et al. | Aug 2002 | B1 |
6440168 | Cauthen | Aug 2002 | B1 |
6447544 | Michelson | Sep 2002 | B1 |
6447546 | Bramlet et al. | Sep 2002 | B1 |
6447547 | Michelson | Sep 2002 | B1 |
6451025 | Jervis | Sep 2002 | B1 |
6454804 | Ferree | Sep 2002 | B1 |
6468301 | Amplatz et al. | Oct 2002 | B1 |
6468302 | CoC et al. | Oct 2002 | B2 |
6478823 | Michelson | Nov 2002 | B1 |
6482235 | Lambrecht et al. | Nov 2002 | B1 |
6488710 | Besselink | Dec 2002 | B2 |
6491724 | Ferree | Dec 2002 | B1 |
6494883 | Ferree | Dec 2002 | B1 |
6508839 | Lambrecht et al. | Jan 2003 | B1 |
6514255 | Ferree | Feb 2003 | B1 |
6520991 | Huene | Feb 2003 | B2 |
6533817 | Norton et al. | Mar 2003 | B1 |
6554833 | Levy et al. | Apr 2003 | B2 |
6562074 | Gerbec et al. | May 2003 | B2 |
6582431 | Ray | Jun 2003 | B1 |
6582467 | Teitelbaum et al. | Jun 2003 | B1 |
6585770 | White et al. | Jul 2003 | B1 |
6592589 | Hajianpour | Jul 2003 | B2 |
6592625 | Cauthen | Jul 2003 | B2 |
6595998 | Johnson et al. | Jul 2003 | B2 |
6602291 | Ray et al. | Aug 2003 | B1 |
6607530 | Carl et al. | Aug 2003 | B1 |
6607544 | Boucher et al. | Aug 2003 | B1 |
6613054 | Scribner et al. | Sep 2003 | B2 |
6623505 | Scribner et al. | Sep 2003 | B2 |
6641587 | Scribner et al. | Nov 2003 | B2 |
6641614 | Wagner et al. | Nov 2003 | B1 |
6645213 | Sand et al. | Nov 2003 | B2 |
6645247 | Ferree | Nov 2003 | B2 |
6648917 | Gerbec et al. | Nov 2003 | B2 |
6648918 | Ferree | Nov 2003 | B2 |
6648920 | Ferree | Nov 2003 | B2 |
6652584 | Michelson | Nov 2003 | B2 |
6656178 | Veldhuizen et al. | Dec 2003 | B1 |
6663647 | Reiley et al. | Dec 2003 | B2 |
6666891 | Boehm, Jr. et al. | Dec 2003 | B2 |
6676665 | Foley et al. | Jan 2004 | B2 |
6679915 | Cauthen | Jan 2004 | B1 |
6685695 | Ferree | Feb 2004 | B2 |
6695760 | Winkler et al. | Feb 2004 | B1 |
6706068 | Ferree | Mar 2004 | B2 |
6706070 | Wagner et al. | Mar 2004 | B1 |
6709458 | Michelson | Mar 2004 | B2 |
6712853 | Kuslich | Mar 2004 | B2 |
6716216 | Boucher et al. | Apr 2004 | B1 |
6716247 | Michelson | Apr 2004 | B2 |
6719773 | Boucher et al. | Apr 2004 | B1 |
6723126 | Berry | Apr 2004 | B1 |
6726691 | Osorio et al. | Apr 2004 | B2 |
6733535 | Michelson | May 2004 | B2 |
6740090 | Cragg et al. | May 2004 | B1 |
6743255 | Ferree | Jun 2004 | B2 |
6746451 | Middleton et al. | Jun 2004 | B2 |
6758863 | Estes et al. | Jul 2004 | B2 |
6793656 | Mathews | Sep 2004 | B1 |
6793679 | Michelson | Sep 2004 | B2 |
6808537 | Michelson | Oct 2004 | B2 |
6814756 | Michelson | Nov 2004 | B1 |
6830589 | Erickson | Dec 2004 | B2 |
6852115 | Kinnett | Feb 2005 | B2 |
6852123 | Brown | Feb 2005 | B2 |
6852129 | Gerbec et al. | Feb 2005 | B2 |
6863673 | Gerbec et al. | Mar 2005 | B2 |
6893464 | Kiester | May 2005 | B2 |
6899716 | Cragg | May 2005 | B2 |
6899719 | Reiley et al. | May 2005 | B2 |
6921264 | Mayer et al. | Jun 2005 | B2 |
6923813 | Phillips et al. | Aug 2005 | B2 |
6923830 | Michelson | Aug 2005 | B2 |
6936065 | Khan et al. | Aug 2005 | B2 |
6936070 | Muhanna | Aug 2005 | B1 |
6948223 | Shortt | Sep 2005 | B2 |
6953477 | Berry | Oct 2005 | B2 |
6955691 | Chae et al. | Oct 2005 | B2 |
6960215 | Olson et al. | Nov 2005 | B2 |
6962606 | Michelson | Nov 2005 | B2 |
6981981 | Reiley et al. | Jan 2006 | B2 |
6988710 | Igarashi | Jan 2006 | B2 |
7008453 | Michelson | Mar 2006 | B1 |
7018415 | McKay | Mar 2006 | B1 |
7018416 | Hanson et al. | Mar 2006 | B2 |
7056321 | Pagliuca et al. | Jun 2006 | B2 |
7060073 | Frey et al. | Jun 2006 | B2 |
7066961 | Michelson | Jun 2006 | B2 |
7077864 | Byrd et al. | Jul 2006 | B2 |
7087055 | Lim et al. | Aug 2006 | B2 |
7094257 | Mujwid et al. | Aug 2006 | B2 |
7097648 | Globerman et al. | Aug 2006 | B1 |
7112206 | Michelson | Sep 2006 | B2 |
7118598 | Michelson | Oct 2006 | B2 |
7135043 | Nakahara et al. | Nov 2006 | B2 |
7166110 | Yundt | Jan 2007 | B2 |
7201751 | Zucherman et al. | Apr 2007 | B2 |
7201775 | Gorensek et al. | Apr 2007 | B2 |
7204853 | Gordon et al. | Apr 2007 | B2 |
7211112 | Baynham et | May 2007 | B2 |
7212480 | Shoji et al. | May 2007 | B2 |
7223292 | Messerli et al. | May 2007 | B2 |
7226475 | Lenz et al. | Jun 2007 | B2 |
7226481 | Kuslich | Jun 2007 | B2 |
7226483 | Gerber et al. | Jun 2007 | B2 |
7238186 | Zdeblick et al. | Jul 2007 | B2 |
7241276 | Argentine et al. | Jul 2007 | B2 |
7241297 | Shaolian et al. | Jul 2007 | B2 |
7241303 | Reiss et al. | Jul 2007 | B2 |
7300440 | Zdeblick et al. | Nov 2007 | B2 |
7309338 | Cragg | Dec 2007 | B2 |
7311713 | Johnson et al. | Dec 2007 | B2 |
7316714 | Gordon et al. | Jan 2008 | B2 |
7318826 | Teitelbaum et al. | Jan 2008 | B2 |
7431735 | Liu et al. | Oct 2008 | B2 |
7452371 | Pavcnik et al. | Nov 2008 | B2 |
7503933 | Michelson | Mar 2009 | B2 |
7507241 | Levy et al. | Mar 2009 | B2 |
7582106 | Teitelbaum et al. | Sep 2009 | B2 |
7601172 | Segal et al. | Oct 2009 | B2 |
7618457 | Hudgins | Nov 2009 | B2 |
7621950 | Globerman et al. | Nov 2009 | B1 |
7625395 | Mückter | Dec 2009 | B2 |
7722674 | Grotz | May 2010 | B1 |
7763028 | Lim et al. | Jul 2010 | B2 |
7828849 | Lim | Nov 2010 | B2 |
7837734 | Zucherman et al. | Nov 2010 | B2 |
7867233 | Shaolian et al. | Jan 2011 | B2 |
7875035 | Boucher et al. | Jan 2011 | B2 |
7879082 | Brown | Feb 2011 | B2 |
8007498 | Mische | Aug 2011 | B2 |
8034110 | Garner et al. | Oct 2011 | B2 |
8105382 | Olmos et al. | Jan 2012 | B2 |
8142507 | McGuckin | Mar 2012 | B2 |
8551171 | Johnson et al. | Oct 2013 | B2 |
8591582 | Anderson et al. | Nov 2013 | B2 |
8709042 | Greenhalgh et al. | Apr 2014 | B2 |
20010007956 | Letac et al. | Jul 2001 | A1 |
20010034552 | Young et al. | Oct 2001 | A1 |
20020007218 | Cauthen | Jan 2002 | A1 |
20020010511 | Michelson | Jan 2002 | A1 |
20020022887 | Huene | Feb 2002 | A1 |
20020032444 | Mische | Mar 2002 | A1 |
20020038767 | Trozera | Apr 2002 | A1 |
20020052656 | Michelson | May 2002 | A1 |
20020068911 | Chan | Jun 2002 | A1 |
20020068939 | Levy et al. | Jun 2002 | A1 |
20020068975 | Teitelbaum et al. | Jun 2002 | A1 |
20020068976 | Jackson | Jun 2002 | A1 |
20020068977 | Jackson | Jun 2002 | A1 |
20020082598 | Teitelbaum | Jun 2002 | A1 |
20020082600 | Shaolian et al. | Jun 2002 | A1 |
20020091390 | Michelson | Jul 2002 | A1 |
20020095155 | Michelson | Jul 2002 | A1 |
20020099378 | Michelson | Jul 2002 | A1 |
20020111688 | Cauthen | Aug 2002 | A1 |
20020120337 | Cauthen | Aug 2002 | A1 |
20020123807 | Cauthen | Sep 2002 | A1 |
20020128713 | Ferree | Sep 2002 | A1 |
20020138077 | Ferree | Sep 2002 | A1 |
20020138133 | Lenz et al. | Sep 2002 | A1 |
20020138144 | Michelson | Sep 2002 | A1 |
20020143401 | Michelson | Oct 2002 | A1 |
20020151896 | Ferree | Oct 2002 | A1 |
20020151980 | Cauthen | Oct 2002 | A1 |
20020156530 | Lambrecht et al. | Oct 2002 | A1 |
20020161367 | Ferree | Oct 2002 | A1 |
20020161373 | Osorio et al. | Oct 2002 | A1 |
20020165542 | Ferree | Nov 2002 | A1 |
20020189622 | Cauthen et al. | Dec 2002 | A1 |
20020198526 | Shaolian et al. | Dec 2002 | A1 |
20030004511 | Ferree | Jan 2003 | A1 |
20030004574 | Ferree | Jan 2003 | A1 |
20030009227 | Lambrecht et al. | Jan 2003 | A1 |
20030014118 | Lambrecht et al. | Jan 2003 | A1 |
20030026788 | Ferree | Feb 2003 | A1 |
20030032963 | Reiss et al. | Feb 2003 | A1 |
20030040796 | Ferree | Feb 2003 | A1 |
20030040798 | Michelson | Feb 2003 | A1 |
20030050701 | Michelson | Mar 2003 | A1 |
20030065394 | Michelson | Apr 2003 | A1 |
20030065396 | Michelson | Apr 2003 | A1 |
20030074076 | Ferree et al. | Apr 2003 | A1 |
20030078579 | Ferree | Apr 2003 | A1 |
20030088249 | Furderer | May 2003 | A1 |
20030120345 | Cauthen | Jun 2003 | A1 |
20030125748 | Li et al. | Jul 2003 | A1 |
20030125807 | Lambrecht et al. | Jul 2003 | A1 |
20030135220 | Cauthen | Jul 2003 | A1 |
20030135279 | Michelson | Jul 2003 | A1 |
20030149482 | Michelson | Aug 2003 | A1 |
20030153976 | Cauthen et al. | Aug 2003 | A1 |
20030158553 | Michelson | Aug 2003 | A1 |
20030158604 | Cauthen et al. | Aug 2003 | A1 |
20030163200 | Cauthen | Aug 2003 | A1 |
20030171813 | Kiester | Sep 2003 | A1 |
20030181979 | Ferree | Sep 2003 | A1 |
20030181980 | Berry et al. | Sep 2003 | A1 |
20030181983 | Cauthen | Sep 2003 | A1 |
20030187507 | Cauthen | Oct 2003 | A1 |
20030187508 | Cauthen | Oct 2003 | A1 |
20030191536 | Ferree | Oct 2003 | A1 |
20030195514 | Trieu et al. | Oct 2003 | A1 |
20030195630 | Ferree | Oct 2003 | A1 |
20030195631 | Ferree | Oct 2003 | A1 |
20030199979 | McGuckin | Oct 2003 | A1 |
20030199981 | Ferree | Oct 2003 | A1 |
20030204189 | Cragg | Oct 2003 | A1 |
20030204260 | Ferree | Oct 2003 | A1 |
20030208270 | Michelson | Nov 2003 | A9 |
20030220643 | Ferree | Nov 2003 | A1 |
20030220650 | Major et al. | Nov 2003 | A1 |
20030220690 | Cauthen | Nov 2003 | A1 |
20030220693 | Cauthen | Nov 2003 | A1 |
20030220694 | Cauthen | Nov 2003 | A1 |
20030233097 | Ferree | Dec 2003 | A1 |
20030233148 | Ferree | Dec 2003 | A1 |
20030233188 | Jones | Dec 2003 | A1 |
20030236520 | Lim et al. | Dec 2003 | A1 |
20040002759 | Ferree | Jan 2004 | A1 |
20040002760 | Boyd et al. | Jan 2004 | A1 |
20040002769 | Ferree | Jan 2004 | A1 |
20040006341 | Shaolian et al. | Jan 2004 | A1 |
20040006344 | Nguyen et al. | Jan 2004 | A1 |
20040010315 | Song | Jan 2004 | A1 |
20040010318 | Ferree | Jan 2004 | A1 |
20040019386 | Ferree | Jan 2004 | A1 |
20040024400 | Michelson | Feb 2004 | A1 |
20040024459 | Ferree | Feb 2004 | A1 |
20040024460 | Ferree | Feb 2004 | A1 |
20040024461 | Ferree | Feb 2004 | A1 |
20040024462 | Ferree et al. | Feb 2004 | A1 |
20040024469 | Ferree | Feb 2004 | A1 |
20040024471 | Ferree | Feb 2004 | A1 |
20040028718 | Ferree | Feb 2004 | A1 |
20040030387 | Landry et al. | Feb 2004 | A1 |
20040030389 | Ferree | Feb 2004 | A1 |
20040030390 | Ferree | Feb 2004 | A1 |
20040030391 | Ferree | Feb 2004 | A1 |
20040030398 | Ferree | Feb 2004 | A1 |
20040034357 | Beane et al. | Feb 2004 | A1 |
20040044410 | Ferree et al. | Mar 2004 | A1 |
20040049289 | Tordy et al. | Mar 2004 | A1 |
20040059418 | McKay et al. | Mar 2004 | A1 |
20040059419 | Michelson | Mar 2004 | A1 |
20040059429 | Amin et al. | Mar 2004 | A1 |
20040068259 | Michelson | Apr 2004 | A1 |
20040082954 | Teitelbaum et al. | Apr 2004 | A1 |
20040082961 | Teitelbaum | Apr 2004 | A1 |
20040087947 | Lim et al. | May 2004 | A1 |
20040087950 | Teitelbaum | May 2004 | A1 |
20040092933 | Shaolian et al. | May 2004 | A1 |
20040092988 | Shaolian et al. | May 2004 | A1 |
20040097927 | Yeung et al. | May 2004 | A1 |
20040111108 | Farnan | Jun 2004 | A1 |
20040133229 | Lambrecht et al. | Jul 2004 | A1 |
20040133280 | Trieu | Jul 2004 | A1 |
20040138673 | Lambrecht et al. | Jul 2004 | A1 |
20040153064 | Foley et al. | Aug 2004 | A1 |
20040153065 | Lim | Aug 2004 | A1 |
20040153146 | Lashinski et al. | Aug 2004 | A1 |
20040167625 | Beyar et al. | Aug 2004 | A1 |
20040172019 | Ferree | Sep 2004 | A1 |
20050010292 | Carrasco | Jan 2005 | A1 |
20050015152 | Sweeney | Jan 2005 | A1 |
20050033431 | Gordon et al. | Feb 2005 | A1 |
20050038512 | Michelson | Feb 2005 | A1 |
20050043796 | Grant et al. | Feb 2005 | A1 |
20050070911 | Carrison et al. | Mar 2005 | A1 |
20050080422 | Otte et al. | Apr 2005 | A1 |
20050085910 | Sweeney | Apr 2005 | A1 |
20050107863 | Brown | May 2005 | A1 |
20050113919 | Cragg et al. | May 2005 | A1 |
20050113928 | Cragg et al. | May 2005 | A1 |
20050119561 | Kienzle | Jun 2005 | A1 |
20050143827 | Globerman et al. | Jun 2005 | A1 |
20050182463 | Hunter et al. | Aug 2005 | A1 |
20050187558 | Johnson et al. | Aug 2005 | A1 |
20050209698 | Gordon et al. | Sep 2005 | A1 |
20050228391 | Levy et al. | Oct 2005 | A1 |
20050228472 | Case et al. | Oct 2005 | A1 |
20050240188 | Chow et al. | Oct 2005 | A1 |
20050249776 | Chen et al. | Nov 2005 | A1 |
20050261683 | Veldhuizen et al. | Nov 2005 | A1 |
20050261695 | Cragg et al. | Nov 2005 | A1 |
20050261768 | Trieu | Nov 2005 | A1 |
20050261781 | Sennett et al. | Nov 2005 | A1 |
20050278023 | Zwirkoski | Dec 2005 | A1 |
20050278026 | Gordon et al. | Dec 2005 | A1 |
20050278036 | Leonard et al. | Dec 2005 | A1 |
20060004455 | Leonard et al. | Jan 2006 | A1 |
20060015184 | Winterbottom et al. | Jan 2006 | A1 |
20060022180 | Selness | Feb 2006 | A1 |
20060036241 | Siegal | Feb 2006 | A1 |
20060036273 | Siegal | Feb 2006 | A1 |
20060052788 | Thelen et al. | Mar 2006 | A1 |
20060052870 | Ferree | Mar 2006 | A1 |
20060058807 | Landry et al. | Mar 2006 | A1 |
20060058876 | McKinley | Mar 2006 | A1 |
20060058880 | Wysocki et al. | Mar 2006 | A1 |
20060079898 | Ainsworth et al. | Apr 2006 | A1 |
20060085069 | Kim | Apr 2006 | A1 |
20060085070 | Kim | Apr 2006 | A1 |
20060089715 | Truckai et al. | Apr 2006 | A1 |
20060095123 | Flanagan | May 2006 | A1 |
20060100706 | Shadduck et al. | May 2006 | A1 |
20060106460 | Messerli et al. | May 2006 | A1 |
20060122701 | Kiester | Jun 2006 | A1 |
20060129244 | Ensign | Jun 2006 | A1 |
20060142858 | Colleran et al. | Jun 2006 | A1 |
20060142859 | McLuen | Jun 2006 | A1 |
20060149239 | Winslow et al. | Jul 2006 | A1 |
20060149349 | Garbe | Jul 2006 | A1 |
20060149385 | McKay | Jul 2006 | A1 |
20060155379 | Heneveld et al. | Jul 2006 | A1 |
20060161261 | Brown et al. | Jul 2006 | A1 |
20060178694 | Greenhalgh et al. | Aug 2006 | A1 |
20060184188 | Li et al. | Aug 2006 | A1 |
20060184248 | Edidin et al. | Aug 2006 | A1 |
20060189999 | Zwirkoski | Aug 2006 | A1 |
20060200166 | Hanson et al. | Sep 2006 | A1 |
20060206207 | Dryer et al. | Sep 2006 | A1 |
20060241764 | Michelson | Oct 2006 | A1 |
20060253201 | McLuen | Nov 2006 | A1 |
20060264968 | Frey et al. | Nov 2006 | A1 |
20060265077 | Zwirkoski | Nov 2006 | A1 |
20060287725 | Miller | Dec 2006 | A1 |
20060287726 | Segal et al. | Dec 2006 | A1 |
20060287727 | Segal et al. | Dec 2006 | A1 |
20060287729 | Segal et al. | Dec 2006 | A1 |
20060287730 | Segal et al. | Dec 2006 | A1 |
20070027363 | Gannoe et al. | Feb 2007 | A1 |
20070032791 | Greenhalgh | Feb 2007 | A1 |
20070043440 | William et al. | Feb 2007 | A1 |
20070055377 | Hanson et al. | Mar 2007 | A1 |
20070067034 | Chirico et al. | Mar 2007 | A1 |
20070067035 | Falahee | Mar 2007 | A1 |
20070093897 | Gerbec et al. | Apr 2007 | A1 |
20070093899 | Dutoit et al. | Apr 2007 | A1 |
20070112428 | Lancial | May 2007 | A1 |
20070118222 | Lang | May 2007 | A1 |
20070123986 | Schaller | May 2007 | A1 |
20070162135 | Segal et al. | Jul 2007 | A1 |
20070173824 | Rosen | Jul 2007 | A1 |
20070173830 | Rosen | Jul 2007 | A1 |
20070173939 | Kim et al. | Jul 2007 | A1 |
20070173940 | Hestad et al. | Jul 2007 | A1 |
20070208423 | Messerli et al. | Sep 2007 | A1 |
20070213717 | Trieu et al. | Sep 2007 | A1 |
20070233260 | Cragg | Oct 2007 | A1 |
20070244485 | Greenhalgh et al. | Oct 2007 | A1 |
20070255408 | Castleman et al. | Nov 2007 | A1 |
20070255409 | Dickson et al. | Nov 2007 | A1 |
20070260270 | Assell et al. | Nov 2007 | A1 |
20070270956 | Heinz | Nov 2007 | A1 |
20070270968 | Baynham et al. | Nov 2007 | A1 |
20070276377 | Yundt | Nov 2007 | A1 |
20070288028 | Gorensek et al. | Dec 2007 | A1 |
20080015694 | Tribus | Jan 2008 | A1 |
20080021558 | Thramann | Jan 2008 | A1 |
20080021559 | Thramann | Jan 2008 | A1 |
20080071356 | Greenhalgh et al. | Mar 2008 | A1 |
20080082162 | Boismier et al. | Apr 2008 | A1 |
20080125865 | Abdelgany | May 2008 | A1 |
20080133012 | McGuckin | Jun 2008 | A1 |
20080140082 | Erdem et al. | Jun 2008 | A1 |
20080140179 | Ladisa | Jun 2008 | A1 |
20080140207 | Olmos et al. | Jun 2008 | A1 |
20080147193 | Matthis et al. | Jun 2008 | A1 |
20080147194 | Grotz et al. | Jun 2008 | A1 |
20080188941 | Grotz | Aug 2008 | A1 |
20080208255 | Siegal | Aug 2008 | A1 |
20080221687 | Viker | Sep 2008 | A1 |
20080243254 | Butler | Oct 2008 | A1 |
20080294205 | Greenhalgh et al. | Nov 2008 | A1 |
20090018524 | Greenhalgh et al. | Jan 2009 | A1 |
20090024204 | Greenhalgh et al. | Jan 2009 | A1 |
20090024217 | Levy et al. | Jan 2009 | A1 |
20090143859 | McClellan et al. | Jun 2009 | A1 |
20090149956 | Greenhalgh et al. | Jun 2009 | A1 |
20090163918 | Levy et al. | Jun 2009 | A1 |
20090182336 | Brenzel et al. | Jul 2009 | A1 |
20090198338 | Phan | Aug 2009 | A1 |
20090234398 | Chirico et al. | Sep 2009 | A1 |
20100004750 | Segal et al. | Jan 2010 | A1 |
20100004751 | Segal et al. | Jan 2010 | A1 |
20100016905 | Greenhalgh et al. | Jan 2010 | A1 |
20100082109 | Greenhalgh et al. | Apr 2010 | A1 |
20100125274 | Greenhalgh et al. | May 2010 | A1 |
20100324560 | Suda | Dec 2010 | A1 |
20110009869 | Marino et al. | Jan 2011 | A1 |
20110054621 | Lim | Mar 2011 | A1 |
20110106260 | Laurence et al. | May 2011 | A1 |
20110125266 | Rodgers et al. | May 2011 | A1 |
20110319898 | O'Neil et al. | Dec 2011 | A1 |
20110320000 | O'Neil et al. | Dec 2011 | A1 |
Number | Date | Country |
---|---|---|
19710392 | Jul 1999 | DE |
0734702 | Oct 1996 | EP |
0758541 | Feb 1997 | EP |
2900814 | Nov 2007 | FR |
2000-210315 | Aug 2000 | JP |
2003-512887 | Apr 2003 | JP |
2004-531355 | Oct 2004 | JP |
2004-321348 | Nov 2004 | JP |
662082 | May 1979 | SU |
WO 8803781 | Jun 1988 | WO |
WO 9214423 | Sep 1992 | WO |
WO 9531945 | Nov 1995 | WO |
WO 9603092 | Feb 1996 | WO |
WO 9700054 | Jan 1997 | WO |
WO 0030523 | Jun 2000 | WO |
WO 0044321 | Aug 2000 | WO |
WO 0044319 | Aug 2000 | WO |
WO 0132099 | May 2001 | WO |
WO 0178625 | Oct 2001 | WO |
WO 0195838 | Dec 2001 | WO |
WO 0213700 | Feb 2002 | WO |
WO 0232347 | Apr 2002 | WO |
WO 03003943 | Jan 2003 | WO |
WO 03003951 | Jan 2003 | WO |
WO 2005062900 | Jul 2005 | WO |
WO 2005096975 | Oct 2005 | WO |
WO 2005120400 | Dec 2005 | WO |
WO 2006023514 | Mar 2006 | WO |
WO 2006023671 | Mar 2006 | WO |
WO 2006026425 | Mar 2006 | WO |
WO 2006028971 | Mar 2006 | WO |
WO 2006034396 | Mar 2006 | WO |
WO 2006034436 | Mar 2006 | WO |
WO 2006037013 | Apr 2006 | WO |
WO 2006042334 | Apr 2006 | WO |
WO 2006050500 | May 2006 | WO |
WO 2006060420 | Jun 2006 | WO |
WO 2006072941 | Jul 2006 | WO |
WO 2006076712 | Jul 2006 | WO |
WO 2006086241 | Aug 2006 | WO |
WO 2006096167 | Sep 2006 | WO |
WO 2006116761 | Nov 2006 | WO |
WO 2006132945 | Dec 2006 | WO |
WO 2007009107 | Jan 2007 | WO |
WO 2007009123 | Jan 2007 | WO |
WO 2007016368 | Feb 2007 | WO |
WO 2007038611 | Apr 2007 | WO |
WO 2007041698 | Apr 2007 | WO |
WO 2007047098 | Apr 2007 | WO |
WO 2007050322 | May 2007 | WO |
WO 2007056433 | May 2007 | WO |
WO 2007062080 | May 2007 | WO |
WO 2007075411 | Jul 2007 | WO |
WO 2007079021 | Jul 2007 | WO |
WO 2007084257 | Jul 2007 | WO |
WO 2007084268 | Jul 2007 | WO |
WO 2007084810 | Jul 2007 | WO |
WO 2007100591 | Sep 2007 | WO |
WO 2007113808 | Oct 2007 | WO |
WO 2007123920 | Nov 2007 | WO |
WO 2007124130 | Nov 2007 | WO |
WO 2007126622 | Nov 2007 | WO |
WO 2007130699 | Nov 2007 | WO |
WO 2007131026 | Nov 2007 | WO |
WO 2007133608 | Nov 2007 | WO |
WO 2007140382 | Dec 2007 | WO |
WO 2008005627 | Jan 2008 | WO |
WO 2009067568 | May 2009 | WO |
WO 2012027490 | Mar 2012 | WO |
Entry |
---|
Database WPI, Week 198004, Thomson Scientific, London, GB; AN 1980-A8866C, XP002690114, -& SU 662 082 A1 (Tartus Univ) May 15, 1979 (May 15, 1979), abstract, figures 1,2. |
Pyo, R. et al., “Targeted Gene Disruption of Matrix Metalloproteinase-9 (Gelatinase B) Suppresses Development of Experimental Abdominal Aortic Aneurysms,” J. Clinical Investigation, 105(11):1641-1649, Jun. 2000. |
Tambiah, J. et al., “Provocation of Experimental Aortic Inflammation Mediators and Chlamydia Pneumoniae,” Brit., J. Surgery, 88(7):935-940, Feb. 2001. |
Walton, L.J. et al., “Inhibition of Prostoglandin E2 Synthesis in Abdonminal Aortic Aneurysms,” Circulation, 48-54, Jul. 6, 1999. |
Xu, Q. et al., “Sp1 Increases Expression of Cyclooxygenase-2 in Hypoxic Vascular Endothelium,” J. Biological Chemistry, 275(32):24583-24589, Aug. 2000. |
Choi, G. et al., “Percutaneous Endoscopic Lumbar Discemtomy by Transiliac Approach,” Spine, 34(12):E443-446, May 20, 2009. |
Franklin, I.J. et al., “Uptake of Tetracycline by Aortic Aneurysm Wall and Its Effect on Inflammation and Proteolysis,” Brit. J. Surger, 86(6):771-775, Jun. 1999. |
Number | Date | Country | |
---|---|---|---|
20080183204 A1 | Jul 2008 | US |
Number | Date | Country | |
---|---|---|---|
60699576 | Jul 2005 | US | |
60752183 | Dec 2005 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US2006/027601 | Jul 2006 | US |
Child | 12014006 | US |